Literature DB >> 32612878

Pharmacological, physiological, and familial factors in propranolol-induced visions.

Emmanuelle A D Schindler1.   

Abstract

Entities:  

Year:  2020        PMID： 32612878      PMCID： PMC7292560          DOI： 10.1212/CPJ.0000000000000698

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  7 in total

1.  Clonidine abuse in a methadone-maintained, clonazepam-abusing patient.

Authors:  Emmanuelle A D Schindler; Dimas J Tirado-Morales; Donald Kushon
Journal:  J Addict Med       Date:  2013 May-Jun       Impact factor: 3.702

2.  Depressed melatonin secretion in patients with nightmares due to beta-adrenoceptor blocking drugs.

Authors:  K Brismar; L Mogensen; L Wetterberg
Journal:  Acta Med Scand       Date:  1987

3.  Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.

Authors:  A Westerlund
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Inflammatory biomarkers in psychosis and clinical high risk populations.

Authors:  Shannon Delaney; Brian Fallon; Armin Alaedini; Robert Yolken; Alyssa Indart; Tianshu Feng; Yuanjia Wang; Daniel Javitt
Journal:  Schizophr Res       Date:  2018-11-08       Impact factor: 4.939

5.  Familial liability for metoprolol-induced psychosis.

Authors:  L Rietveld; T van der Hoek; M H C T van Beek; A F A Schellekens
Journal:  Gen Hosp Psychiatry       Date:  2015-06-25       Impact factor: 3.238

6.  Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia.

Authors:  Mikkel Arendt; Preben B Mortensen; Raben Rosenberg; Carsten B Pedersen; Berit L Waltoft
Journal:  Arch Gen Psychiatry       Date:  2008-11

7.  Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.

Authors:  Keiko Kamakura; Hitoshi Mochizuki; Ken-ichi Kaida; Akira Hirata; Mami Kanzaki; Toshihiro Masaki; Ryohji Nakamura; Kazuo Motoyoshi
Journal:  Parkinsonism Relat Disord       Date:  2004-06       Impact factor: 4.891
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.